-
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore, Glen Burnie
-
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
NCT05170126 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: Female
· Maryland: Bethesda
-
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Maryland: Baltimore, Bethesda
-
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
NCT05849467 ·
Phase: Phase 1 ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
NCT00794352 ·
Phase: Not specified ·
Ages: 1 Month to 99 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis
NCT06441617 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore
-
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
NCT02784210 ·
Phase: Phase 2 ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281 ·
Phase: Phase 3 ·
Ages: 40 Years to 70 Years ·
Sex: All (male and female)
· Maryland: Olney
-
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
NCT06864936 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
Genes and Environment in Multiple Sclerosis
NCT01353547 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Bethesda
-
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248 ·
Phase: Not specified ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
NCT01730131 ·
Phase: Not specified ·
Ages: 2 Years to 120 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292 ·
Phase: Phase 3 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
Pathological Basis of MRI Signal Changes in Multiple Sclerosis
NCT02659956 ·
Phase: Not specified ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Maryland: Rockville, Towson
-
Role of Genetic Factors in the Development of Lung Disease
NCT00001532 ·
Phase: Not specified ·
Ages: 2 Years to 90 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
NCT06170970 ·
Phase: Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
Study of COYA 302 for the Treatment of ALS
NCT07161999 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
Study of Skin Tumors in Tuberous Sclerosis
NCT00001975 ·
Phase: Not specified ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
NCT07389590 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
Study of the Disease Process of Lymphangioleiomyomatosis
NCT00001465 ·
Phase: Not specified ·
Ages: 16 Years to 100 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· Maryland: Lutherville
-
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
NCT07221240 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
TSC Biosample Repository and Natural History Database
NCT05676099 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Maryland: Silver Spring
-
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
NCT07497399 ·
Phase: Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Maryland: Baltimore
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
NCT03109288 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 120 Years ·
Sex: All (male and female)
· Maryland: Bethesda
-
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
NCT03816345 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Maryland: Baltimore, Bethesda
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
NCT06796504 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 22 Years to 60 Years ·
Sex: All (male and female)
· Maryland: Baltimore